PE Funding for Life Sciences Companies in India: Deal Structures and Valuations

India's life sciences sector spans pharmaceutical companies, medical device manufacturers, diagnostics businesses, biotech platforms, and contract research organisations. Private equity investment in this broad sector has grown substantially, driven by India's global competitive position in manufacturing, its large pool of scientific talent, and the structural growth of healthcare demand both domestically and in export markets. For life sciences founders and promoters, understanding how PE investors evaluate businesses in this sector and how deals are structured is the first step toward accessing institutional capital.

Key Takeaways

• Life sciences PE investment in India covers pharma, biotech, medtech, diagnostics, and CROs, with each sub-sector requiring a tailored investor targeting and positioning strategy.
• IP strength, regulatory approval status, and revenue quality are the three highest-weighted valuation factors in life sciences PE transactions.
• Deal structures in life sciences PE range from growth equity minority investments to milestone-linked convertible instruments designed to align valuation with clinical or regulatory value creation events.

‍

The Life Sciences PE Landscape in India

India's life sciences ecosystem has evolved considerably over the past two decades from a primarily generics-focused manufacturing base into a diversified innovation and services platform. Today, the sector encompasses large-scale generics and API manufacturers, emerging biosimilar and biologic companies, medical device manufacturers competing in both domestic and export markets, contract research organisations serving global clinical trial requirements, and diagnostics businesses spanning everything from pathology laboratories to advanced genomics platforms.

PE investment across this broad life sciences landscape has accelerated significantly. Global healthcare-focused PE funds, India-dedicated funds with a life sciences mandate, and sovereign wealth funds with long-horizon capital are all actively deploying capital. The investment thesis varies by sub-sector: for pharmaceutical businesses it centres on manufacturing competitiveness and product pipelines; for biotech it centres on IP value and regulatory milestones; for medtech it centres on clinical outcomes and market penetration in underpenetrated healthcare settings.

The COVID-19 pandemic was a catalyst for increased PE interest in Indian life sciences. It demonstrated the global dependence on Indian pharmaceutical manufacturing, highlighted the need for domestic diagnostic infrastructure, and accelerated innovation in healthcare delivery models. PE investors drew three lessons from the pandemic: Indian life sciences companies are globally indispensable, domestic healthcare infrastructure is severely undercapitalised, and healthcare technology adoption is faster than previously assumed. These lessons continue to shape capital allocation decisions.

Positioning your life sciences business correctly within this investment landscape begins with identifying which PE funds are active in your specific sub-sector and understanding their investment criteria. Our private equity india sector guide provides the broader context, while our specific guides on pharma PE and medical devices and diagnostics PE cover the adjacent sub-sectors in depth.

Why Life Sciences Companies Are Attracting PE Capital

Several structural factors make Indian life sciences companies particularly attractive to PE investors. The first is the manufacturing cost advantage. Indian life sciences businesses produce pharmaceutical ingredients, generic drugs, diagnostics reagents, and certain medical devices at a fraction of the cost of equivalent production in the US or Europe. This cost advantage, when combined with regulatory compliance to international standards, creates a competitive position that is very difficult for high-cost market players to replicate.

The second structural driver is India's scientific talent depth. India produces a significant proportion of the world's pharmaceutical scientists, biochemists, biomedical engineers, and clinical researchers. This talent pool underpins the innovation capabilities of Indian life sciences companies and enables research-intensive activities at a cost level that makes global biotechnology and medtech companies strongly interested in India as a development and manufacturing partner.

The third driver is the global demand for affordable, quality life sciences products. Generic drugs, biosimilars, diagnostics kits, and lower-cost medical devices are in growing demand globally, particularly in emerging markets and in healthcare systems facing affordability pressures. Indian life sciences companies are uniquely positioned to serve this demand, and PE investors see this positioning as a long-term structural advantage rather than a cyclical opportunity.

Fourth, India's domestic healthcare market is itself a significant and growing opportunity. Rising incomes, insurance penetration, and health awareness are creating growing domestic demand for quality pharmaceuticals, diagnostic services, and medical devices. Life sciences companies with strong domestic market positions can build a stable revenue foundation that complements export-driven growth.

Valuation Frameworks for Life Sciences Businesses

Life sciences businesses are among the most complex to value in PE transactions because the appropriate methodology varies significantly by sub-sector and business maturity. Mature generics manufacturers with stable revenues and established customer relationships are valued primarily on EBITDA multiples. High-growth CDMOs and specialty pharma companies often attract revenue multiple valuations that reflect the expected future EBITDA trajectory. Early-stage biotech and medtech businesses with limited revenues but significant IP and pipeline value require a risk-adjusted pipeline valuation approach.

For pharma and CDMO businesses, EBITDA multiples in Indian PE transactions typically range from 10x to 18x, with the specific multiple determined by the regulatory track record, product portfolio quality, customer concentration, and growth trajectory. Businesses at the upper end of this range are characterised by US FDA-approved facilities, a portfolio of complex or differentiated products, diversified customer relationships, and a demonstrated track record of consistent EBITDA margin expansion.

For diagnostics and medical device businesses, both EBITDA and revenue multiples are used, with the applicable methodology depending on the growth stage of the business. High-growth diagnostics businesses expanding rapidly across multiple cities may be valued at 5x to 8x revenue, while mature, stable diagnostics chains with established multi-location networks are more typically valued at 12x to 16x EBITDA. Medical device companies with proprietary technology often receive a hybrid valuation incorporating both current financial metrics and a pipeline adjustment for products in development.

Biotech and novel therapeutic platform companies present the most complex valuation challenge. PE investors in this category use a risk-adjusted net present value methodology for each product in the pipeline, assigning probabilities of technical and regulatory success at each development milestone, estimating the commercial opportunity upon approval, and discounting the resulting cash flows to present value. The aggregate rNPV across the pipeline, adjusted for the company's operating costs and capital requirements, forms the basis of the enterprise valuation.

Common Deal Structures in Life Sciences PE

Life sciences PE deals in India employ a range of structures tailored to the specific circumstances of each transaction. Growth equity minority investments are the most common structure for profitable, growing businesses that are seeking capital to expand capacity, file additional regulatory submissions, or accelerate geographic expansion. In this structure, the PE fund acquires a stake of 25% to 45%, the founder retains control, and agreed governance rights protect the investor's interests.

Milestone-linked convertible instruments are particularly suited to life sciences businesses where significant value creation events, such as a US FDA approval, a major customer contract award, or a clinical trial completion, are expected during the investment horizon. In this structure, the initial investment is made at a conservative valuation in the form of compulsorily convertible debentures, which convert to equity at a pre-agreed formula upon the achievement of specified milestones. This structure aligns the valuation with the actual value creation rather than promising outcomes that have not yet been achieved.

Structured equity with royalty components is used in transactions involving IP-intensive businesses where the PE investor seeks both equity participation and a current return from the IP asset. In this structure, the PE fund acquires an equity stake and simultaneously enters into a royalty arrangement where a specified percentage of revenues from defined products or territories is paid as a royalty until a cap is reached. This structure provides the PE fund with current income while sharing the equity upside with the founder.

Control or buyout transactions are less common in early-stage life sciences but do occur in mature businesses, particularly in the context of promoter succession, multinational company carve-outs, or consolidation plays where a PE fund is building a larger platform through a series of acquisitions. In these transactions, the PE fund acquires a controlling or full stake, typically with acquisition financing from specialised healthcare lenders, and implements a value creation plan under its own operational direction.

IP, Pipeline and Regulatory Moats That Attract Investors

Intellectual property is the foundational value driver in most life sciences PE investments. For pharmaceutical companies, the relevant IP includes formulation patents for novel drug delivery systems, process patents for API synthesis, data exclusivity for new chemical entities, and regulatory exclusivities attached to first-to-file ANDA approvals in the US market. Each of these IP assets has a quantifiable economic value that PE investors will assess during due diligence, with guidance from specialist IP valuation advisors.

A deep and diversified regulatory filing pipeline is viewed as a strategic moat by PE investors. Companies with a large number of pending ANDA filings in the US, multiple marketing authorisation applications in European markets, or a robust domestic product registration pipeline are better positioned to sustain revenue growth across the investment horizon than those dependent on a small number of approved products. The pipeline depth and the probability of each filing achieving approval are key inputs to the PE investment thesis.

For medical device companies, regulatory clearances including US FDA 510(k) or PMA approvals, CE marking for European markets, and CDSCO approvals for the domestic market represent significant moats. These approvals take years and substantial investment to obtain and create barriers to entry that protect the valuation of the approved products. Devices with both domestic and international regulatory clearances command significantly higher valuations than those with only domestic approvals.

Proprietary manufacturing processes and trade secrets are also valuable IP assets in life sciences PE transactions. CDMO businesses with proprietary processes for complex dosage form manufacturing, or API companies with unique synthesis routes that deliver superior yield or purity, have competitive advantages that are difficult to replicate and that support premium valuations. These proprietary capabilities should be carefully documented and protected with appropriate confidentiality agreements, trade secret protocols, and where applicable, patent filings before the PE process begins.

Preparing Your Life Sciences Company for PE Investment

Life sciences companies seeking PE investment should begin their preparation process at least 18 months before they plan to approach investors. The preparation process covers financial, regulatory, operational, and legal dimensions, each of which requires specific actions to achieve the standard that PE investors expect.

Financial preparation begins with ensuring that three years of audited accounts are available, prepared by a reputable firm and clearly presenting revenues by product, geography, and customer. For early-stage businesses with limited revenues but significant expenses, the financial statements should be supplemented by a detailed burn rate analysis and a clear explanation of the milestones that each tranche of investor capital will fund. A five-year financial model with bottom-up revenue projections and clearly articulated assumptions is essential for any PE investor presentation.

Regulatory preparation is particularly critical in life sciences. Engage a specialist regulatory consultant to conduct an internal audit of your facility and quality systems before the PE process begins. Any observations should be addressed systematically, and the remediation actions should be documented in a format that can be shared with investors during due diligence. Maintaining a clean regulatory correspondence file with all agency interactions clearly organised is an important signal of operational discipline.

IP consolidation and protection is a pre-process priority for any life sciences business with proprietary technology or formulation. Ensure that all relevant patents are filed, that ownership of IP assets is clearly vested in the business entity rather than individuals, and that all employee invention assignment agreements are in place. PE investors will conduct detailed IP due diligence, and any ambiguities in IP ownership can create significant complications that delay or derail the transaction.

Management Team and Scientific Advisory Boards

For life sciences businesses seeking PE investment, the management team must combine scientific credibility with commercial execution capability. PE investors want to see leaders who can translate scientific or technical capability into revenue, margins, and market share. Where the founding team is primarily scientific, bringing in a commercially experienced CEO or COO, and potentially establishing a scientific advisory board of respected external experts, significantly strengthens the investor's confidence in the business's ability to execute its growth plan.

How FinLead Supports Life Sciences Capital Raises

FinLead's advisory team has worked across the life sciences spectrum, from pharmaceutical manufacturers and CDMOs to diagnostics businesses and medtech companies. Our team understands the specific investor criteria, due diligence dimensions, and deal structuring approaches that life sciences PE transactions require. We bring established relationships with the PE funds most active in Indian life sciences and know how to position your business to earn their conviction.

Our engagement for life sciences clients begins with a comprehensive PE-readiness assessment covering financial, regulatory, IP, and operational dimensions. We work with you to address any gaps identified in this assessment before investor engagement begins. This preparation phase is the highest-return investment a life sciences business can make before a PE raise.

If you are a life sciences founder or promoter exploring PE funding, contact FinLead today. Our team will assess your business's PE potential and outline a clear path to closing a successful capital raise.

‍

Frequently Asked Questions

What types of life sciences companies attract PE investment in India?

Pharmaceutical manufacturers, CDMOs, API companies, diagnostics businesses, medical device companies, biotech platforms, and contract research organisations all attract PE investment in India. The specific PE fund type and investment thesis vary significantly by sub-sector.

How are early-stage biotech companies valued for PE investment?

Early-stage biotech companies are valued using a risk-adjusted net present value approach, where each pipeline product is assigned a probability of regulatory success and the expected commercial value upon approval is discounted to present value. The aggregate rNPV across the pipeline forms the enterprise valuation basis.

What is the typical PE holding period for life sciences investments in India?

PE holding periods in Indian life sciences typically range from four to eight years. Biotech and novel platform investments may extend to ten years given the longer timeline required to progress from development to commercial scale.

What is a milestone-linked convertible instrument and when is it used?

A milestone-linked convertible debenture converts from debt to equity upon the achievement of specified value creation events such as regulatory approvals or revenue targets. This structure is used in life sciences PE when the current valuation is uncertain but specific events will confirm the business's value proposition.

How important is export revenue for life sciences PE valuation in India?

Export revenues from regulated markets are highly valued in life sciences PE transactions. They validate the quality standard of the business, carry higher margins than domestic revenues in many sub-sectors, and represent a more scalable growth platform aligned with global demand for affordable life sciences products.

What role does IP play in life sciences PE due diligence?

IP is a primary valuation driver in life sciences PE transactions. PE investors assess the patent portfolio, regulatory exclusivities, proprietary manufacturing processes, and trade secrets of the business. Clear IP ownership vested in the company entity, not individuals, is a prerequisite for any serious PE engagement.

Can a pre-revenue biotech company raise PE investment in India?

Pre-revenue biotech companies can raise PE investment from specialised life sciences funds with the risk appetite and analytical capability to evaluate early-stage platforms. These funds are relatively few in India, and most prefer businesses with at least proof-of-concept data and a clear path to clinical or commercial milestones within the investment horizon.

How does FinLead support a life sciences company preparing for PE?

FinLead conducts a comprehensive PE-readiness assessment for life sciences clients covering financial, regulatory, IP, and operational dimensions. We prepare the investor materials, target the most relevant PE funds, and manage the structured process from initial investor engagement through to financial close.

‍